Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Poly-(ADP-ribose) polymerase (PARP) inhibitors exploit synthetic lethality in cancers with homologous recombination DNA repair (HRR) defects, such as those caused by BRCA mutations.
• Prostate cancer is increasingly recognized as having a higher prevalence of HRR deficiency than previously understood.
• The clinical efficacy of PARP inhibitors olaparib and rucaparib has been demonstrated in HRR-deficient metastatic castration-resistant prostate cancer.

Purpose of the Study:

• To review the current landscape of PARP inhibitors in prostate cancer research.
• To summarize published and ongoing clinical trials involving PARP inhibitors for prostate cancer treatment.

Main Methods:

• Literature review of published studies on PARP inhibitors in prostate cancer.
• Analysis of ongoing clinical trials investigating PARP inhibitors in various prostate cancer settings.
• Focus on trials involving HRR-deficient and metastatic castration-resistant prostate cancer.

Main Results:

• Olaparib and rucaparib have achieved US FDA approval for HRR-altered metastatic castration-resistant prostate cancer.
• Clinical trials have shown the effectiveness of PARP inhibitors in specific prostate cancer patient populations.
• Combination strategies involving PARP inhibitors with other therapies are under extensive investigation.

Conclusions:

• PARP inhibitors represent a significant advancement in the treatment of specific prostate cancer subtypes.
• Ongoing research is exploring novel combinations to enhance therapeutic outcomes.
• The role of PARP inhibitors in prostate cancer is expanding, with a focus on precision medicine approaches.